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Abstract
The third variable region (V3) of the human immunodeficiency virus type 1 (HIV-1) envelope gp120 subunit participates in
determination of viral infection coreceptor tropism and host humoral immune responses. Positive charge of the V3 plays a
key role in determining viral coreceptor tropism. Here, we examined by bioinformatics, experimental, and protein modelling
approaches whether the net positive charge of V3 sequence regulates viral sensitivity to humoral immunity. We chose HIV-1
CRF01_AE strain as a model virus to address the question. Diversity analyses using CRF01_AE V3 sequences from 37
countries during 1984 and 2005 (n=1361) revealed that reduction in the V3’s net positive charge makes V3 less variable due
to limited positive selection. Consistently, neutralization assay using CRF01_AE V3 recombinant viruses (n=30) showed that
the reduction in the V3’s net positive charge rendered HIV-1 less sensitive to neutralization by the blood anti-V3 antibodies.
The especially neutralization resistant V3 sequences were the particular subset of the CCR5-tropic V3 sequences with net
positive charges of +2t o+4. Molecular dynamics simulation of the gp120 monomers showed that the V3’s net positive
charge regulates the V3 configuration. This and reported gp120 structural data predict a less-exposed V3 with a reduced net
positive charge in the native gp120 trimer context. Taken together, these data suggest a key role of the V3’s net positive
charge in the immunological escape and coreceptor tropism evolution of HIV-1 CRF01_AE in vivo. The findings have
molecular implications for the adaptive evolution and vaccine design of HIV-1.
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Introduction
The third variable region (V3) of human immunodeficiency
virus type 1 (HIV-1) envelope gp120 subunit participates in
determination of viral infection coreceptor tropism [1,2]. It is
usually composed of 35 amino acids, which form a loop-like
structure on the gp120 monomer [3,4]. The V3 and the conserved
outer domain of gp120 create the binding surface for viral
infection coreceptors after the binding of gp120 to the primary
infection receptor CD4 [4,5]. These interactions and successive
conformational changes of gp120 are essential in rendering the
initially occluded hydrophobic domain of the envelope gp41
subunit available to fusion with cellular plasma membrane.
The HIV-1 V3 is highly variable. In parallel with the V3
sequence variation, many types of infection coreceptors are
reported. These are the members of the G protein-coupled
receptor superfamily. The two most common types of infection
coreceptors in humans are the CC chemokine receptor 5 (CCR5)
and the CXC chemokine receptor 4 (CXCR4) [6]. Notably, a
single group of the HIV-1 variants using the CCR5 (R5 virus [6])
predominates during the first several to 10 years or more of
persistent infection in vivo [7,8]. Other tropism variants including
CXCR4-tropic variants (X4 virus [6]) can grow at early stage of
infection by needle stick injuries, but are replaced with the R5
viruses after seroconversion [9,10]. They generally grow better
only during progression to AIDS. The R5 and X4 viruses are
distinguishable by sequence feature of V3: the R5 V3 amino acid
sequences generally have a lower net positive charge than those of
X4 [3,11]. Only a few basic substitutions in V3 can switch the viral
coreceptor tropism from CCR5 to CXCR4 [12,13]. Considering
the extremely high levels of mutation rate of HIV-1, these findings
suggest that strong selective forces are continually purifying the R5
viruses during long-lasting persistent infection.
The HIV-1 V3 is highly immunogenic, tolerant to change, and
variable presumably to evade immune recognition [14–16]. HIV-
infected individuals make high levels of anti-V3 antibodies that are
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er, they often react poorly or only with low affinity to the native,
oligomeric form of the gp120 protein [17,18]. The inaccessibility
of the oligomeric envelope protein is particularly prominent in the
primary HIV-1 isolates [19–21], which are usually the R5 viruses.
Indeed, studies with limited set of viruses have shown that
antibodies reactive with the R5-virus V3s tend to bind to the
monomeric but not the oligomeric gp120s [22,23], and they
poorly neutralize the R5 viruses [23–25]. In contrast, antibodies
against X4-virus V3s usually bind to both forms of gp120s [22,23],
and they potently neutralize the X4 viruses [23–25]. Consistent
with the lower sensitivity of R5 viruses to anti-V3 antibody
neutralization, positive selection for amino acid variation is less
prominent in the R5 virus V3 sequences, and V3 amino acid
sequences of the R5 virus are relatively homogeneous among virus
isolates [26,27] or in infected individuals [28–30] compared with
those of the X4 viruses.
While the immunological escape, variation, and coreceptor
tropism evolution of HIV-1 is an important issue from both
clinical and scientific viewpoints, current studies are largely
confined to those of HIV-1 subtype B from North America and
Europe. In this study, we attempted to obtain and integrate
information on HIV-1 CRF01_AE strain [31] circulating in
Southeast Asia. Specifically, we examined whether net positive
charge of HIV-1 CRF01_AE V3 sequence regulates viral
sensitivity to humoral immunity. Here, we demonstrate by
combining bioinformatics, experimental, and protein modelling
approaches that the reduction in net positive charge of HIV-1
CRF01_AE V3 sequence reduces viral sensitivity to humoral
immunity and simultaneously confers viral CCR5 tropism. The
findings suggest a key role of the V3 net positive charge in the
immunological escape, variation, and the coreceptor-tropism
evolution of HIV-1 CRF01_AE in vivo.
Results
Correlation of HIV-1 CRF01_AE V3 net positive charge, V3
prevalence, and V3 diversity.
A previous case study has suggested that a group of CRF01_AE
V3 sequences for the viral CCR5 tropism is resistant to the selective
force for amino acid variation [29,30]. To extend this finding with
three infected individuals, we conducted large-scale analysis of V3
diversity using public database information. V3 sequences of the
CRF01_AE strain were extracted from the HIV Sequence
Database (http://www.hiv.lanl.gov/content/hiv-db/mainpage.
html). A single V3 amino acid sequence per infected individual
was randomly extracted. Sequences with ambiguous bases are
excluded from the analysis. V3 sequences (n=1361, 35 amino acid
length) from 37 countries during 1984 and 2005 (see supporting
information Figs. S1a and S1b) were used for the diversity analysis.
The 1361 V3 sequences were divided intotwo subsets, ‘‘a’’ and ‘‘b’’,
which lack and have the glycosylation motif, respectively. Each
group was divided into subgroups on the basis of the net charge;
arginine, lysine, and histidine were counted as +1, aspartic acid and
glutamic acid as 21, and other amino acids as 0.
Although there are exceptions, the V3 amino acid sequences
capable of directing the viral CCR5 tropism of the CRF01_AE
strain generally have net positive charges of +2t o+4 and the
conserved N-linked glycosylation motif (asparagine-X-threonine/
serine) at positions 6 to 8 [29,30]. Consistent with the dominance of
the R5 viruses in humans, less positively charged, glycosylated V3
sequences for the CCR5 tropism (2b, 3b, and 4b) were dominant in
the database for over 15 years, independent of the sampling period
(Fig. 1A and Fig. S1c). Shannon entropy scores representing amino
acid variation were relatively low for the most abundant 3b V3
compared to those for the 7a V3 for the CXCR4 tropism (Fig. 1B),
consistent with previous report [3]. Nucleotide substitutions for
amino acid change were more suppressed in the V3s for the CCR5
tropism compared with those for the CXCR4 tropism (Fig. 1C).
The 3b V3 had the lowest ratio of nonsynonymous to synonymous
substitutions (dn/ds) with about 0.6, and acquisition of a glycosyl-
ation site decreased the dn/ds ratios (P=0.001, Table S1). The dn/ds
ratios correlated positively with the Shannon entropies, with lower
dn/ds ratios for lower entropies (Fig. 1D). Similar effects of the net
positive charge of V3 on V3 diversity were detected in other major
genetic lineages of HIV-1 circulating in the world, such as subtypes
A, B, and C (Fig. S2).
If the low levels of amino acid changes in the V3 structures for
CCR5 tropism involved the elimination of new mutants in natural
selection, negative values for Tajima’s D statistic would be
expected [32]. Indeed, Tajima’s D statistic was significantly
negative for 2b and 3b V3s (P=0.01, Fig. 1E and Table S2).
Together, these findings on V3 diversity provide further evidence
that the V3 sequences for the CCR5-tropism are less variable in
nature due to the limited positive selection for amino acid diversity
compared with those for CXCR4 tropism.
Correlation of HIV-1 CRF01_AE V3 net positive charge,
HIV-1 neutralization sensitivity, and HIV-1 coreceptor
tropism.
A positive selection pressure for the V3 diversity can be the
humoral immunity. To examine whether the V3 net positive
charge regulates HIV-1 neutralization sensitivities to the anti-V3
antibodies, we used V3 recombinant viruses (n=30). The
recombinant viruses have the CRF01_AE V3s in the backbone
of the X4 virus gp120 of HIV-1 subtype B, LAI strain [13,30,33].
The V3s were from HIV-1 proviral DNA clones in the peripheral
blood mononuclear cells of three infected individuals at the
asymptomatic stage or AIDS [13,30,33]. These V3s could be
grouped into the 2b (n=2), 3b (n=4), 4b (n=5), 5b (n=3), 6b
(n=5), 3a (n=1), 4a (n=2), 5a (n=3), 6a (n=3), and 7a (n=2)
sequences (Fig. S3). The 2b, 3b, and 4b V3 clones were the most
prevalent in the three infected individuals examined, and their
sequences were mostly identical [29], consistent with the V3
prevalence and diversity data in this study. The neutralization
sensitivity of each recombinant virus was assessed with a single-
round viral infectivity assay [34]. In parallel, titers of plasma
antibody reactive with the V3 elements of the recombinant viruses
were measured with V3-peptide-based, enzyme-linked immuno-
sorbent assay (ELISA) [35].
When the V3 synthetic peptide of the parental virus of the
recombinantviruseswasused forthe immunoassay,theCRF01_AE
plasma samples had only traces of binding antibodies (Fig. 2B,
Absorbance of LAI). The blood samples failed to neutralize this
virus (Fig. 2B, ND50 of LAI). Thus, the blood samples tested are
lacking in anti-V3 binding antibodies, as well as neutralization
antibodies against the parental subtype B virus. The results agree
with low levels of V3 amino acid identities between subtype B and
CRF01_AE strains (http://www.hiv.lanl.gov/content/hiv-db/
mainpage.html). They also agree with the assumption that V3
sequence diversity causes neutralization escape of HIV-1.
All blood samples from CRF01_AE infected individuals
contained antibodies that bound to the synthetic peptides from
the CRF01_AE strain V3 sequences of the recombinant viruses
(Fig. 2B, Absorbance of 2b to 7a). Coincidentally, they neutralized
a group of the viruses having particular V3 sequences (Fig. 2B).
The neutralization-sensitive viruses had V3s lacking a glycosyla-
tion site (3a, 4a, 5a, 6a, 7a, n=11), or V3s having a glycosylation
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The neutralization activities were abrogated by protein G pre-
treatment of the plasma samples (Fig. S4), showing that
neutralization is indeed mediated by antibodies in the plasma
samples.
Notably, the blood samples poorly neutralized a group of V3
recombinant viruses(Fig.2B,ND50of2b,3b,and4b,n=11).These
viruses had weakly charged V3s and had an N-glycosylation site,
which are the characteristics of V3s for CCR5 tropism (Fig. S3, V3
IDs of 2b, 3b, and 4b). The lack of neutralization activities was not
Figure 1. V3 net positive charge influences V3 diversity. HIV-1 CRF01_AE V3 sequences (n=1361) were grouped on the basis of net positive
charge and glycosylation capability (A) Distribution of the V3 structural variants of HIV-1 CRF01_AE in the public database. (B) Shannon entropy
scores [3] on primary and three-dimensional structures of 3b and 7a V3s. AE-c, 3b-c, and 7a-c indicate consensus sequences for all CRF01_AE
sequences, 3b V3 group (n=576), and 7a V3 group (n=21), respectively. (C) Median (diamond) and interquartile range (vertical bar) of ratios of dn/ds,
(D) Relation of median dn/ds ratios and average Shannon entropy scores, and (E) Tajima’s D statistic values [32] for each V3 structural group.
doi:10.1371/journal.pone.0003206.g001
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recombinant viruses. The blood samples contained high levels of
antibodies that bound to the 2b, 3b, and 4b V3 peptides, more so
than of other V3 groups (Fig. S5 and Fig. 2B, Absorbance of 2b, 3b,
and 4b). The results are consistent with the high levels of prevalence
and limiteddiversity of these V3 sequences (Fig. 1).The study shows
that the group of V3 elements for CCR5 tropism is highly
immunogenic, whereas binding antibodies raised in humans
generally show only weak neutralization activities. This neutraliza-
tion-resistant phenotype associated with particular V3 group was
observed reproducibly in a multiple-round infectivity assay,
suggesting that the phenotype is intrinsic to the viruses (Fig. S6).
The relation of this neutralization-resistant phenotype and
HIV-1 coreceptor tropism was examined using information on
coreceptor usages of the V3 recombinant viruses [13,30,33].
Importantly, the V3s having the viral-resistant phenotype
unexceptionally rendered HIV-1 CCR5-tropic (Fig. 2C, left panel,
V3 groups of 2b, 3b, and 4b, n=10). On the other hand, V3s
conferring CCR5 tropism did not always render HIV-1 resistant
(Fig. 2C, V3 groups of 3a, 4a, 5a, and 5b, n=7). Thus, the V3s
Figure 2. Reduction in V3 net positive charge causes loss of HIV-1 neutralization sensitivity to blood antibodies against V3 PND. (A)
Genome structure of the V3 recombinant viruses (n=30) [13,30,33]. (B) Blood anti-V3 antibody titers and viral neutralization sensitivity to the blood
antibodies. Plasma samples (n=20) were obtained from CRF01_AE positive individuals. Plasma antibody binding activities to the synthetic peptides
corresponding to each V3 PND of the recombinant viruses were measured by V3-peptide-based ELISA [35] (Absorbance at 450 nm). The same plasma
samples were used to measure ND50 against recombinant viruses in a single-round infectivity assay using CD4
+CXCR4
+CCR5
+ HeLa cells [34]
(Neutralization). Medians (diamond) and interquartile ranges for individual V3 structural groups are shown. (C) Neutralization sensitivity and
coreceptor tropism. The recombinant viruses were grouped into CCR5-tropic (left) and CXCR4-tropic (right) variants using data reported previously
[13,30,33].
doi:10.1371/journal.pone.0003206.g002
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elements associated with viral CCR5 tropism. In contrast, all V3s
associated with viral CXCR4 tropism and CCR5/CXCR4 dual
tropism rendered HIV-1 susceptible to neutralization (Fig. 2C, V3
groups of 4b, 5a, 5b, 6a, 6b, and 7a, n=13).
The group of viruses having 4b V3s were neutralization-
resistant only when they had the CCR5-restricted tropism (Fig. 2C,
4b in left and right panels). The 4b V3s associated with viral
neutralization resistance had no basic substitutions compared with
the CRF01_AE consensus (Fig. S3, recombinant IDs of A1, A2,
A4, and A5). By contrast, the neutralization-sensitive version had
two basic substitutions (Fig. S3, recombinant ID of B10). The
results may imply that V3 basic substitutions at particular positions
in addition to the overall net positive charge play a critical role in
the determination of viral neutralization sensitivity and coreceptor
tropism.
We further examined whether a CCR5-tropic but not a
CXCR4-tropic envelope of CRF01_AE strain is linked to viral
resistant to neutralization by anti-V3 antibodies. For this purpose,
we used a pair of nearly isogenic R5 and X4 virus clones that have
3b and 5a V3, respectively [36,37]. The results obtained with these
clones and 35 blood specimens were consistent with present study
and indicated that the CCR5-tropic but not the CXCR4-tropic
envelope protein of the HIV-1 CRF01_AE strain was linked to
viral resistance to neutralization with anti-V3 antibodies in the
blood (data not shown).
HIV-1 V3 net positive charge and V3 conformation
To obtain molecular insights into the roles of the V3 net positive
charge in regulating HIV-1 neutralization sensitivity, we conduct-
ed computer-aided structural analysis. Currently, X-ray structure
information on the HIV-1 R5 virus gp120 monomer bound with
soluble CD4 [3] is available in the Protein Data Bank. With the
data, we attempted to obtain a gp120 monomer structure for the
pre-CD4 binding stage to address initial V3 conformation before
receptor interaction. We first constructed gp120 outer domain
models of the V3 recombinant viruses used in this study by a
homology modelling method. Molecular dynamics (MD) simula-
tion was then performed with the homology models.
Figure 3A shows examples of the MD simulation of two
recombinant virus gp120s with 3b and 7a V3 elements. The TH09
V3 (3b V3) is from an HIV-1 CRF01_AE infected asymptomatic
patient, identical to the CRF01_AE V3 consensus sequence (Fig.
S3, recombinant ID of TH09), rendered HIV-1 neutralization-
resistant and CCR5-tropic (Fig. 2C, left panel). The B1 V3 (7a V3)
is from an AIDS patient, more positively charged (Fig. S3,
recombinant ID of B1) and rendered HIV-1 neutralization-
sensitive and CXCR4-tropic (Fig. 2C, right panel).
The MD simulations show that V3 configuration is nearly
equilibrated up to 5 nanoseconds of simulation times (Fig. 3A).
Notably, the TH09 V3 was equilibrated at a much more distant
position from the b20b21 loop in the outer domain than the B1
V3 (Figs. 3A and B). Hydrogen bonds were formed around the
TH09 V3 base between D330 and R332, and D330 and R424,
which contributed to stabilizing the V3 configuration (Fig. 3C).
However, the hydrogen bonds were not formed with the gp120
having the B1 V3 (Fig. S7). Coulombic repulsion between B1 V3
and R424 increased about 44-fold as compared with that of TH09
V3, with electrostatic energies of +2.0 and +0.045 kcal/mole for
B1 and TH09, respectively. The repulsion was greatest on the
R424 residue in the gp120 outer domain. The results suggest that
an increase in the V3 net positive charge influences electrostatic
balance at the V3 base.
Importantly, the amino acids around the V3 base are relatively
conserved in nature. The D330 and R332 are located at the V3
base and highly conserved within each subtype of the HIV-1 M
group in the public database (Fig. 3D). The conservation was seen
even in the V3s for the CXCR4 tropism (Fig. 1B). The R424 is in
the fourth constant region (C4) of the gp120 core, and
neighbouring amino acids are also conserved. The CRF01_AE
strain alone has lysine at position 424, whereas K424 is conserved
within the CRF01_AE. These data suggest that most HIV-1
gp120 monomers have the potential to stabilize V3 configuration
at the base and that basic amino acid substitutions in V3 have
strong influences on the V3 configuration.
The MD simulation data were incorporated into those of a
gp120 trimer structure obtained by cryoelectron microscopy [38]
to illustrate schematically the V3 position in the native gp120
trimer (Fig. 4). Some glycans are also schematically illustrated at
the appropriate regions. The models predict that less positively
charged V3 protrudes into the outer domain of the neighboring
gp120 monomer, whereas V3 with increased net positive charge
protrudes away from the neighboring monomer in the trimer
context.
Discussion
HIV-1 is the causative agent of AIDS and is responsible for
more than 2 million deaths every year. Understanding the
immunological escape, variation, and coreceptor tropism evolu-
tion of HIV-1 is critical for developing strategies for anti-HIV
interventions. In this regard, current studies are largely confined to
those of HIV-1 subtype B from North America and Europe. In this
study, we focused on the study of HIV-1 CRF01_AE strain
circulating in Southeast Asia. The HIV-1 CRF01_AE is one of the
five major HIV-1 subtypes circulating in the world [31] and thus
an important strain for public health of Asia, as well as of world.
However, much less basic information are available as compared
with the HIV-1 subtype B.
We first demonstrate with bioinformatics approach using 1361
sequences in public database that CRF01_AE V3’s net positive
charge influences V3 diversity and prevalence. We found that the
net positive charge of V3 influences V3 diversity (Fig. 1).
Acquisition of the N-glycosylation motif in V3 augmented the
sequence conservation. Our data of dn/ds ratios and Tajima’s D
statistic provide strong evidence that the reduction in V3 diversity
is due to limited positive selection for amino acid changes. These
findings are compatible with previous findings with subtype B that
sequence diversity is smaller among R5 virus V3s [26–28].
Moreover, the findings demonstrate the generality of findings
obtained with an intra-familial infection case of CRF01_AE
infection [29,30]. The evidence that the V3 net positive charge
influences V3 diversity is not solely based on sequence analysis.
Structural and neutralization data suggest that V3 net positive
charge regulates V3 diversity by controlling V3 structure and
neutralization sensitivities, as discussed below.
We next examined potential causes of the differential diversity
of CRF01_AE V3 sequences. We demonstrated with neutraliza-
tion assay of V3 recombinant viruses that the V3 net positive
charge influences HIV-1 neutralization sensitivity. We found that
reduction in the net positive charge of V3 caused reduction in viral
neutralization sensitivity to the blood anti-V3 antibodies in
infected humans (Fig. 2). Again, acquisition of the N-glycosylation
motif in V3 augmented the effect. We further confirmed that the
especially neutralization resistant V3 sequences all render HIV-1
CCR5 tropic (Fig. 2C). These results are compatible with previous
findings with subtype B that R5 viruses are more refractory to anti-
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these findings suggest that anti-V3 antibodies can act as a positive
selection pressure to increase V3 sequence diversity and that V3
positive net charge can influence V3 diversity by regulating
neutralization sensitivity to the V3 antibodies.
Importantly, present data revealed that not all the CCR5-tropic
V3 sequences render HIV-1 resistant to the neutralization. Some
V3 sequences lacking N-glycosylation site or those have the
glycosylation site but have net positive charge of +5 conferred
CCR5 tropism on HIV-1, whereas they were relatively sensitive to
the antibody neutralization (Fig. 2C). These data are consistent
with findings on CRF01_AE V3 sequence diversity and preva-
lence in this study. Together, the data suggest that a particular
subset of CRF01_AE V3 for CCR5 tropism confers a selective
advantage on HIV-1 in the face of humoral immunity and that the
anti-V3 antibodies may be an important selective force to
maintain CCR5-tropic V3 sequences with limited amino acid
changes during persistent infection.
We further examined molecular mechanisms of neutralization
escape. We found with MD simulation that reductions in the net
positive charge of V3 caused a shift of V3 position in the gp120
monomer (Fig. 3). This is the first indication that the net positive
charge of V3 regulates V3 configuration in the gp120 monomer. By
incorporating our MD data into experimental data of HIV-1 gp120
structures [3,4,38], we proposed a model of V3 masking that
explains how the net positive charge of V3 regulates HIV-1 V3
neutralization sensitivity (Fig. 4). The model explains present
Figure 3. MD simulation of the HIV-1 gp120 outer domain. The V3 subset conferring the neutralization-resistant phenotype is referred to in
this study as rV3: it has net positive charges of +2t o+4, an N-glycosylation site, and a capability to direct viral CCR5 tropism. The non-rV3 renders HIV-
1 more susceptible to blood antibody neutralization. It has net positive charges of greater than +4 and a capability to direct viral CXCR4 tropism. (A)
Examples of the MD simulation of two recombinant virus p120 outer domains with rV3 (TH09) and non-rV3 (B1). Distance between the Ca atom of
P318 at the V3 tip and the Ca atom of Q433 at the b20b21 loop were monitored for 5 nanoseconds. (B) Superimposition of the gp120 monomers
with the TH09 V3 (blue) or B1 V3 (red) at the simulation time of 5 nanoseconds. (C) Close-up view of the base-stem region of the TH09 V3. Orange
dotted lines around the tip of the orange arrow indicate three hydrogen bonds at the V3 base. (D) Shannon entropy scores of the amino acids at the
positions of 330, 332, and 424 in the public database. The positions in the gp120 of the HIV-1LAI [48] are used for the amino acid numbering.
doi:10.1371/journal.pone.0003206.g003
Figure 4. Models for the self-directed masking of V3 by
mutations for the CCR5 tropism. The MD data in Fig. 3 and the
HIV-1 gp120 trimer structure from cryoelectron microscopy [38] were
used to construct the gp120 trimer models with CCR5-tropic (left) or
CXCR4-tropic (right) V3. The models were made so that the MD data
and experimental data [3,4,38] are compatible.
doi:10.1371/journal.pone.0003206.g004
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chargedV3 forCCR5 tropismpositionsinthe gp120 trimer context
such that it protrudes into the outer domain of the neighboring
gp120 monomer, which will inevitably result in better protection of
V3 from antibodies by the glycans. This model also explains why
anti-V3 antibodies bind effectively to monomeric but not native,
oligomeric form of the gp120 protein of the HIV-1 R5 viruses [22–
25]. Further structural studies are under way to assess the model.
Our study provides molecular insights into the mechanisms of
coreceptor-tropism evolution of HIV-1. Due to high levels of viral
mutation rate, vigorous and continual viral replication in vivo, and
viral tolerance to V3 mutations, many viable HIV-1 V3 mutants
would be continuously generated during a persistent infection.
Therefore, why only the R5 virus dominates during persistent
infection is a long-lasting question in HIV-1 research. Our study
suggests a selective advantage of a subset of CCR5-topic V3
sequences in the face of humoral immunity: self-masking of
neutralization epitope by reduction in net positive charge. Higher
levels of the dn/ds ratios for more positively charged V3 sequences
for CXCR4 tropism (Figs. 1C and D) may imply that the X4
viruses might persist as a minority, continually receive positive
selection pressures for amino acid changes, and outgrow only
when the host immunity is severely damaged.
It will be important to examine why neutralization resistant V3
sequences exclusively direct viral CCR5 usage (Fig. 2C). The
distinct V3 configuration in gp120 may contribute to the
restriction of coreceptor type to be interacted, because amino
acid residues at the V3 base directly participate in the binding to
the N-terminal region of CCR5 [4]. In addition, structural
differences among chemokine receptors may contribute. For
example, the N-terminal region of CXCR4 is glycosylated,
whereas that of CCR5 is not. The glycosylated V3 for
neutralization resistance will sterically interrupt the access to the
glycosylated coreceptor. Indeed, the removal of the N-linked
glycosylation sites from CXCR4 allows the protein to serve as a
universal coreceptor for both X4 and R5 viruses [39]. Further
structural studies are under way to address this issue.
Our study has implications for HIV-1 vaccine design. The data
suggests that a key impediment to the clinical use of Gp120 as an
immunogen may be the cryptic nature of the R5 virus V3
neutralization epitope. A simple strategy to use R5 virus Gp120 will
be insufficient even if the Gp120 of circulating HIV-1 subtype is
carefully selected as immunogen. To develop strategies that could
circumvent or overcome the impediment may be critical for practical
application of Gp120 vaccine. In this regard, the amino acids that
contribute to forming V3 conformation for the epitope masking
through hydrogen bonds are relatively conserved among HIV-1
major subtypes in the world (Fig. 3D). Therefore, intervention in
these interactions might be a target for a new strategy to improve
effectiveness of immunological control of HIV-1.
In conclusion, we have identified here structural and functional
features of HIV-1 CRF01_AE V3 elements those allow HIV-1 less
sensitive to antibody neutralization. To our knowledge, this is the
first report to show that the net positive charge of a neutralization
epitope regulates viral sensitivity to humoral immunity. Thus,
amino acid substitutions altering charged status of antigen site
appear to deserve more attention, particularly in the adaptive
evolution of HIV-1, as well as the other rapidly evolving pathogen.
Materials and Methods
Analysis of sequence diversity
Grouping of the sequences was done computationally using a
software system, InforSense BioSense V3 (InforSense Ltd. http://
www.inforsense.com).Nonsynonymousand synonymousnucleotide
substitutions were calculated for all pair-wise sequence comparisons
within each V3 subgroup using the Perl version of SNAP (Los
Alamos HIV sequence database) according to the Nei and Gojobori
method [40] incorporating the statistical method developed by Ota
and Nei [41]. Amino acid variation at individual V3 positions was
calculated according to the method described in the report by
Huang et al [3] on the basis of Shannon’s equation [42]:
Hi ðÞ~{
X
xi
px i ðÞ log2 px i ðÞxi ~ G, A, I, V, :::::: ðÞ ,
where H(i), p(xi),a n di indicate the amino acid entropy score of a
given position, the probability of occurrence of a given amino acid
at the position, and the number of the position, respectively. An H(i)
score of zero indicates absolute conservation, whereas 4.4 indicates
complete randomness. The H(i) scores were expressed in the V3
sequence or in the three-dimensional structures constructed by the
MD simulation method described below. The p(xi) scores were used
to construct a consensus for each V3 structural group. Tajima’s D
statistic [32] for each typeof V3 sequence populationwas calculated
using DnaSP 4.10 [43].
Blood specimens
Plasma samples were obtained from HIV-1 CRF01_AE positive
individuals with written informed consent at Yokohama City
University Hospital in Japan according to the rule of the ethics
committee of the hospital. The clinical stages of the patients at the
time of blood collection were A1 (n=4), A2 (n=4), B3 (n=3), C2
(n=1), C3 (n=7), and unknown (n=1) according to the 1993
Revised Classification System (CDC, USA). The CD4
+ T-cell
counts and HIV-1 RNA levels ranged from 2610
3 to 3719610
3 /
ml blood (mean=243610
3 /ml) and from ,50 to 7.5610
5 copies/
ml blood (mean=2.4610
4 copies/ml), respectively. All plasma
samples were heat-inactivated at 56uC for 30 minutes prior to use.
Anti-V3 antibody titration
V3-peptide-based ELISA [35] was carried out using synthetic
peptides matching to the central 19 amino acids of the V3 regions
of the recombinant viruses (Fig. S3). Synthetic peptides were
coated on 96-well plates (Immulon II; Dynatech Laboratories,
Virginia, USA) and reacted with diluted plasma samples (1/10
4).
Antibodies bound to the peptides were detected with anti-human
IgG peroxidase conjugate and 3,39,5,59-tetramethylbenzidine
substrate (TMB peroxidase EIA substrate Kit, Bio-Rad Labora-
tories, USA). Each plasma sample was tested in duplicate.
Neutralization assays
Plasmid DNAs containing HIV-1 V3 recombinant proviruses
(n=30) were constructed by the overlap extension method
[13,30,33]. Cell-free viruses were prepared by transfection of the
plasmid DNAs into HeLa cells as described previously [13,30,33].
Neutralization activities were measured in a single-round viral
infectivity assay using CD4
+CXCR4
+CCR5
+ HeLa cells [34].
Equal infectious titers of viruses (300 blue-cell-forming units) were
incubated with serially diluted plasma samples (1/10 to 1/10
3) for
60 min at 37uC. The infected cells were cultured for 48 hours at
37uC, fixed, and stained with 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside. Each plasma dilution was tested in duplicate,
and the means of the positive blue cell numbers were used to
calculate the 50% inhibition dose of viral infectivity (ND50). For
plasma samples that did not neutralize a virus at the lowest
dilution tested (1:10), an arbitrary titer of 1:5 (50 ND50 /ml) was
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a multiple-round viral infectivity assay using NP-2 cell lines [44].
Equal infectious titers of the viruses (100 tissue culture infectious
dose) were incubated with serially diluted plasma samples (1/10 to
1/10
3) for 60 min at 37uC and used to infect the CD4
+CXCR4
+
NP-2 cells and CD4
+CCR5
+ NP-2 cells. After 60 min, the cells
were washed once with phosphate-buffered saline. Culture
supernatants were collected at 5 days after infection, and amounts
of HIV-1 Gag p24 proteins were measured with a commercially
available kit (RETROtek HIV-1 p24 Antigen ELISA, ZeptoMe-
trix Corporation, USA). Each plasma dilution was tested in
duplicate, and the means of the p24 amounts were used to
calculate the ND50.
HIV-1 coreceptor usages
Previous data of the coreceptor tropisms of the recombinant
viruses [13,30,33] were used.
MD simulation
Gp120 outer domain structures bearing various V3 elements
were constructed with the homology modelling technique, using the
Molecular Operating Environment, MOE 2006.08 (Chemical
Computing Group Inc., Montreal, Quebec, Canada) as described
[45,46]. As the modelling template, we used the crystal structure of
HIV-1 gp120 containing an entire V3 element at a resolution of
3.30A ˚ (PDB code: 2B4C), which represents the structure after the
CD4 binding [3]. The 251amino-terminal and 24 carboxyl-
terminal residues were deleted to construct the gp120 outer domain
structure. MD simulations were performed using the SANDER
module in the AMBER 8 program package [47] with MDGRAPE-
3 (http://mdgrape.gsc.riken.jp/) and the AMBER parm99 force
field with the TIP3P water model. After heating calculations for 20
picoseconds until 310 K using the NVT ensemble, the simulations
were executed using the NPT ensemble at 1 atm and at 310 K for 5
nanoseconds. Superimpositions of the structures were done by
coordinating atoms of amino acids along the b-sheet at the V3 base.
Supporting Information
Figure S1 Information on the V3 sequences for the diversity
analyses. Shown are the % distributions of CRF01_AE V3
sequences used in the present study (n=1361) as a function of
sampling years (a), countries (b), and V3 structural group (c). The
sequences during 1991 to 2005 (n=1148) represent a majority.
They are mostly from Asia (15 countries, 1219 sequences). Others
arefromAfrica(7countries,52sequences),Europe (10countries,47
sequences), other regions (5 countries, 36 sequences), and unknown
(1 sequence). V3 groups having CCR5 tropism (2b, 3b and 4b)
represent the majority independent of the sampling period.
Found at: doi:10.1371/journal.pone.0003206.s001 (0.34 MB TIF)
Figure S2 V3 diversity of HIV-1 subtypes A, B, and C. Global
distribution (left) and dn/ds ratios (right) of V3 structural variants of
HIV-1 subtypes A, B, and C were examined, using the HIV-1
public database information from June 2007, and plotted as
described in Fig. 1C.
Found at: doi:10.1371/journal.pone.0003206.s002 (0.31 MB TIF)
Figure S3 V3 amino acid sequences of the recombinant viruses.
V3 sequences of the recombinant viruses are from CRF01_AE
clones in uncultured peripheral blood mononuclear cells from a
Japanese family [30] (V3 IDs of A1{similar, tilde operator }A9 and
B1{similar, tilde operator }B13), A1 variants having naturally
occurringbasic amino acid substitutions(mt1{similar,tilde operator
}mt8) [13], and TH09 isolate having the CRF01_AE consensus V3
sequence [33] (TH09). Deduced amino acids of the V3 sequences
were aligned with the CRF01_AE consensus sequence, ENSI-c.
Thesmallblue openboxindicatesa potentialN-linkedglycosylation
site conserved in the V3 structural group b. Red letters indicates
basic amino acid substitutions with respect to ENSI-c. The large
black box indicates 19 amino acid sequences used for V3-peptide
ELISA in Fig. 2. The net charge is the number of positively charged
amino acids (R, K, and H) minus the number of negatively charged
amino acids (D and E). Coreceptor tropism of the recombinant
viruses was determined using CD4
+CXCR4
+ HOS cells and
CD4
+CCR5
+ HOS cells [13,30,33].
Found at: doi:10.1371/journal.pone.0003206.s003 (0.39 MB TIF)
Figure S4 Effects of protein G on plasma neutralizing activities.
The plasma samples (YM17 and YM61) were incubated with
serially diluted protein G agarose solution (GammaBind Plus
Sepharose, Amersham) for 60 min at 37uC. The agarose was
removed by brief centrifugation, and the supernatants were used
to measure ND50 against LAI recombinant viruses having non-
rV3 (B1 and B10) using CD4
+CXCR4
+CCR5
+ HeLa cells
(MAGIC-5 cells [34]) as described in Materials and Methods.
Found at: doi:10.1371/journal.pone.0003206.s004 (0.21 MB TIF)
Figure S5 Antibody epitope mapping of the rV3. Peptide-based,
enzyme-linked immunosorbent assay [35] was carried out using
indicated synthetic peptides matching the rV3 amino acids of the
recombinant viruses (SI Fig. 3, recombinant ID of A1). Antibodies
bound to the peptides were detected with anti-human IgG
peroxidase conjugate and 3,39,5,59-tetramethylbenzidine sub-
strate. Absorbance at 450 nm is shown.
Found at: doi:10.1371/journal.pone.0003206.s005 (0.27 MB TIF)
Figure S6 ND50 in the single- and multiple-round viral infectivity
assays. Plasma samples (n=8) were used to measure ND50 against
LAI recombinant viruses having rV3 (clone IDs of ENSI-c and A1)
and non-rV3 (B6). The ND50 were measured in a single-round viral
infectivity assay using CD4
+CXCR4
+CCR5
+ HeLa cells (MAGIC-
5 cells) [34] or a multiple-round viral infectivity assay using
CD4
+CXCR4
+ NP2 cells and CD4
+CCR5
+ NP2 cells (NP-2 cells)
[44] as described in Materials and Methods. Red diamonds indicate
the medians of the neutralization titers of the 8 plasma samples.
Found at: doi:10.1371/journal.pone.0003206.s006 (0.20 MB TIF)
Figure S7 Close-up view of the V3 base-stem region of Gp120
with non-rV3. LAI Gp120 outer domain structures with B1 V3
were constructed computationally by methods of homology
modelling and molecular dynamic simulation at a simulation time
of 5 nanoseconds.
Found at: doi:10.1371/journal.pone.0003206.s007 (0.64 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0003206.s008 (0.04 MB
PDF)
Table S2
Found at: doi:10.1371/journal.pone.0003206.s009 (0.04 MB
PDF)
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